(Yicai Global) June 5 -- Chinese pharmaceutical company Frontier Biotech has received the go-ahead to proceed with sales of the world’s first long-acting fusion inhibitor of human immunodeficiency virus-1.
China Food and Drug Administration has granted approvals for Albuvirtide, a state-level intravenous drug, independently developed by the Nanjing-based medicine maker, the regulatory body said in a statement.
Albuvirtide can be used jointly with other antiretroviral drugs to treat infected patients who have been treated with antiviral drugs but still suffer from viral replication. Weekly injections, combined with lopinavir or ritonavir, can treat 'patients who experienced first-line regimen failure,' with an efficacy similar to or better than that of the second-line treatment recommended by the World Health Organization, interim data from third-phase clinical trials indicate.
The drug offers a totally new molecular mechanism and has proven effective on pandemic HIV-1 and drug-resistant viruses. Displaying a number of unique features such as a low administration frequency, high resistance barriers, high safety standards and limited side effects, the drug can significantly improve patient medication and improve quality of life.
Editor: William Clegg